Pyxis Oncology Prices $110M Offering, Warrants Add $172.6M

BOSTON — Pyxis Oncology, Inc. (Nasdaq: PYXS) announced on Sept. 30, 2026 the pricing of a registered public offering of 36,047,919 shares of common stock, or pre-funded warrants for certain investors, alongside common warrants to purchase 49,310,352 shares at $3.50 each, for expected gross proceeds of roughly $110 million before fees.

The combined price for each share and accompanying common warrant is $2.90, while each pre-funded warrant and accompanying common warrant is priced at $2.899. If every warrant is exercised in full, the clinical-stage cancer therapeutics developer would receive an additional $172.6 million in gross proceeds.

Context — Why a Two-Tranche Biotech Raise Matters Now

The structure matters because Pyxis did not simply sell stock. It bundled common warrants exercisable at $3.50 into every unit sold at $2.90, effectively offering buyers a long-dated call on the company's lead program. The company said the warrants only become exercisable after stockholders approve a charter amendment increasing authorized shares, and the amendment takes effect.

That condition ties the offering's full economics to a shareholder vote, not just to market demand. Until the Charter Amendment Effective Date, warrant holders cannot convert their positions into stock, which means the $172.6 million in potential additional proceeds is contingent, not banked.

Pyxis said the warrants expire on the earlier of the fifth anniversary of the Charter Amendment Effective Date or the 30th calendar day following the later of that date and public disclosure of overall survival data from its Phase 1 monotherapy study of micvotabart pelidotin in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma.

The company expects that OS data release in the first half of 2027. The dual trigger — charter approval plus data publication — means the warrant clock only starts once both conditions are met, compressing the exercise window into a defined period around a binary clinical readout.

Biotech financings of this shape are common when a company wants to raise cash without fully repricing its equity, but they concentrate dilution risk around a single catalyst. The offering is expected to close on or about Oct. 1, 2026, subject to customary closing conditions, so the share count expands immediately while the warrant overhang lingers until the charter vote.

Data — What the Numbers Show

The headline figure is $110 million in expected gross proceeds, before underwriting discounts, commissions and offering expenses. That is the cash Pyxis can deploy immediately. The secondary figure — $172.6 million — is only realized if all common and pre-funded warrants are exercised in full.

Component	Amount
Common shares offered	36,047,919
Pre-funded warrants offered	1,883,121
Common warrants (underlying shares)	49,310,352
Combined price per share + warrant	$2.90
Combined price per pre-funded warrant + warrant	$2.899
Common warrant exercise price	$3.50
Expected gross proceeds	~$110 million
Additional gross proceeds if fully exercised	~$172.6 million

The math implies the warrant exercise price sits roughly 20.7% above the $2.90 combined offering price, a premium that only pays off for warrant holders if PYXS trades above $3.50 before expiry. Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers.

Pyxis said it intends to use net proceeds to advance MICVO through key clinical milestones, including Headliner, its planned Phase 3 trial in 2L+ R/M HNSCC, plus working capital and general corporate purposes. The company did not disclose the size of underwriting discounts or a projected cash runway in the announcement.

The offering is being made under a registration statement on Form S-3 (File No. 333-291801) previously declared effective by the SEC, with a final prospectus supplement to be filed. All securities in the offering are being sold by Pyxis Oncology, meaning no selling shareholder is cashing out — the entire raise flows to the company.

Analysis — Dilution, Overhang, and the HNSCC Catalyst

The immediate effect for PYXS holders is share count expansion: 36,047,919 new shares plus 1,883,121 pre-funded warrants, against a warrant pool that could add 49,310,352 more shares if exercised. That is the dilution cost of funding a Phase 3 program without a partner.

The counter-argument is that warrant exercise at $3.50 would bring in $172.6 million in fresh capital at a premium to the offering price, which strengthens the balance sheet precisely when the company needs cash for Headliner. For warrant holders, the trade is a defined-risk call on the OS data readout expected in the first half of 2027.

The structure also creates a two-stage overhang. First, the charter amendment vote must pass — a governance event that could fail if shareholder sentiment sours. Second, even if it passes, the warrant expiry is tied to OS data disclosure, meaning the overhang persists until that data lands.

Sector exposure runs through clinical-stage oncology names broadly, since Pyxis is competing for the same investor capital as other R/M HNSCC developers. Merck's KEYTRUDA, which Pyxis is testing MICVO in combination with in a separate Phase 1/2 study, remains the incumbent standard in that indication, and any MICVO data readout will be measured against that benchmark.

Positioning-wise, the offering prices at $2.90 with warrants struck at $3.50, suggesting buyers are willing to underwrite near-term dilution in exchange for upside exposure to a binary 2027 catalyst. The flow is toward event-driven biotech capital, not generalist healthcare funds.

The key risk the company itself flagged: it may need additional funding beyond this raise, and clinical development is lengthy, expensive and uncertain, with potential delays or failures in obtaining regulatory approvals. Warrant exercise is not guaranteed.

Outlook — What to Watch Next

Three catalysts define the near-term path. First, the offering is expected to close on or about Oct. 1, 2026, subject to customary closing conditions. Second, the charter amendment requires stockholder approval before any common warrant becomes exercisable — the company did not disclose a vote date. Third, the OS data release from the Phase 1 monotherapy MICVO study in 2L+ R/M HNSCC is expected in the first half of 2027.

The warrant expiry clock starts only after both the charter amendment is effective and OS data is publicly disclosed, with a 30-day tail after the later of those two dates. That means the exercise window is not fixed in calendar terms — it depends on when the data lands.

No price levels beyond the $2.90 combined offering price and $3.50 warrant strike were disclosed. Traders watching PYXS will likely treat $3.50 as the reference threshold where warrant economics turn favorable for holders, though the company gave no guidance on where it expects the stock to trade.

The company also did not disclose a projected cash runway or the size of underwriting discounts, so the net proceeds figure remains unstated. Those details should appear in the final prospectus supplement filed with the SEC.

Frequently Asked Questions

What does the Pyxis Oncology offering mean for existing PYXS shareholders?

Existing holders face immediate dilution from 36,047,919 new shares plus 1,883,121 pre-funded warrants. A further 49,310,352 shares could be issued if common warrants are exercised at $3.50, though that only happens after stockholder approval of a charter amendment and the company's public disclosure of overall survival data from its Phase 1 MICVO study. The raise funds the planned Phase 3 Headliner trial.